Latest news
Modernising the clinical trial: a shift to decentralised trials driven by advances in technology and catalysed by the COVID-19 pandemic

Nancy Cross, Senior Analyst at Lightning Health presents a research poster at ISPOR Europe 2021 on payer awareness and perceptions of decentralised clinical trials. (POSB278)

Challenges and opportunities for digital therapeutics: key requirements to demonstrate value across the EU, England and the US

Nasos Kipentzoglou presents new research at ISPOR Europe 2021 looking at the current processes for the evaluation of digital therapeutics (DTx), to ensure they meet the requirements of healthcare systems and ultimately, benefit patients. (POSB295)

Cross-border collaboration to support pricing and access for high-cost, high-value therapies: a review of initiatives in Europe

Yasmina Zegaoui and Eleanor Butler present recent research at ISPOR Europe reviewing cross-country collaboration models with a focus on health technology assessment

Germany’s coalition government aims to contain healthcare expenditure by reducing the period of free pricing

Details have emerged regarding the new government’s cost-containment plans for the pharmaceutical budget

World Antimicrobial Awareness Week 2021

Lightning Health is proud to support World Antimicrobial Awareness Week

Lightning Health to present three posters at the Virtual ISPOR Europe 2021

Our expert team will present three posters of their recent work and thinking

The introduction of a pan-European HTA: Shaping the landscape for future ATMP launches

An overview of the recent European policy updates and the implications they may have for the launch of ATMPs in Europe

BeNeLuxA initiative supports the reimbursement of Zolgensma® in Belgium, Ireland and the Netherlands

Yasmina Zegaoui, Consultant at Lightning Health, looks at how this managed entry agreement initiative can enable the reimbursement of a much-needed therapy for patients

Team promotions at Lightning Health

A well deserved congratulations to Nancy and Nasos!

ATMP market access: Advanced Therapies Congress & Expo 2021

Yasmina Zegaoui, Senior Consultant and Nasos Kipentzoglou, Senior Analyst at Lightning Health report on some of the key topics from the two-day event

Supporting the life sciences sector

Take a look at how Lightning Health can support your European launch and patient access strategy

We are hiring!

If you want to join our growing team based in the London office, get in touch!

Lightning Health delighted to be presenting three posters at the Virtual ISPOR Europe 2021!

Our expert team will be presenting three posters of our recent work and thinking

Thinking Outside the Box: Sustainable Solutions to Drive Global Patient Access for Advanced Therapy Medicinal Products (ATMPs)

Lightning Health’s thought-leadership perspective on sustainable solutions to drive global patient access for ATMPs

60 seconds with Maddy Dawson, Analyst

60 seconds with Maddy Dawson, Analyst

60 seconds with Yasmina Zegaoui, Senior Consultant

60 seconds with Yasmina Zegaoui, Senior Consultant

Remdesivir for the treatment of COVID-19: A case study on early market access in Europe

Joshua Beddow, Junior Analyst at Lightning Health takes a look at the early market access for remdesivir in Europe

Lightning Health Ltd. announces the change of the company name to Lightning Health Ltd.

Lightning Health Ltd. today announced the change of the company name to Lightning Health Ltd

Virtual cohorts: a method to overcome challenges in developing evidence in rare and complex diseases?

Eleanor Butler,  Consultant at Lightning Health reviews the use of synthetic data and virtual cohorts to mitigate challenges associated with developing evidence in rare and complex diseases

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: International routes

In the last of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the international routes; the Access Consortium and Project Orbis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Unfettered Access Procedure for marketing authorisations approved in Northern Ireland

In the penultimate of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Unfettered Access Procedure for marketing authorisations approved in Northern Ireland 

Cancard launch marks an important step to improve attitudes towards medicinal cannabis and help reduce fear for those carrying cannabis-based products for medicinal reasons

Following the launch of Cancard in the UK, Nancy Cross, Analyst at Lightning Health talks about the positive impact the launch may have on individuals carrying medicinal cannabis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Decentralised and Mutual Recognition Reliance Procedure

In the fourth of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Decentralised and Mutual Recognition Reliance Procedure 

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: European Commission (EC) Decision reliance procedure

In the third of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health looks at the European Commission Decision reliance procedure

Managing the symptoms of Parkinson’s Disease with medical cannabis: Exploring the patient perspective

Nancy Cross, Analyst at Lightning Health takes a look at the power of the patient perspective and its importance in increasing the understanding of the potential benefits of medical cannabis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: rolling review procedure

In the second of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the rolling review procedure

ATMP Market Access: ensuring sustainable patient access to life-changing therapies

How Lightning Health can support you to navigate your access challenges associated with ATMPs

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: 150-day National Procedure

In the first of a series of articles looking at the mechanisms to obtain marketing authorisation in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the 150-day National Procedure and the possible implications for manufacturers

Retrospective analysis of NICE CAR-T therapy single technology appraisals and identification of strategies to minimise time to patient access

In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit

In the intro of a series of articles, Nasos Kipentzoglou, Analyst at Lightning Health provides a round up of the current mechanisms to obtain marketing authorisation in the UK

The G-BA implements post launch real world evidence generation for Zolgensma®

Nasos Kipentzoglou, Analyst and Eleanor Butler, Consultant at Lightning Health review the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma®

NICE rejects gene therapy Zynteglo

Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning Health explores why the beta thalassaemia treatment is not recommend for routine NHS funding

Implications of the UK Rare Diseases Framework for rare disease patients and manufacturers developing new treatments

Nancy Cross, Analyst, and Eleanor Butler, Consultant at Lightning Health review the recently published framework and discuss what this means for stakeholders

60 seconds with Nancy Cross, Analyst

60 seconds with Nancy Cross, Analyst

Happy Festive Season

The team at Lightning Health would like to…

60 seconds with Nasos Kipentzoglou, Analyst

60 seconds with Nasos Kipentzoglou, Analyst

60 seconds with Joshua Beddow, Junior Analyst

60 seconds with Joshua Beddow, Junior Analyst

60 seconds with Alice Best, Platform and Operations Manager

60 seconds with Alice Best, Platform and Operations Manager

60 seconds with Eleanor Butler, Consultant

60 seconds with Eleanor Butler, Consultant

Why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare

This week our colleagues Eleanor Butler and Marina Kousta attended an ISPOR webinar, read their blog.

60 seconds with Marina Kousta, Analyst

60 seconds with Marina Kousta, Analyst

60 seconds with Stuart Hurst, Executive Advisor (Launch Excellence)

60 seconds with Stuart Hurst, Executive Advisor (Launch Excellence)

60 seconds with Andrew Satherley, Joint Managing Director

60 seconds with Andrew Satherley, Joint Managing Director

60 seconds with James Whitehouse, Joint Managing Director

60 seconds with James Whitehouse, Joint Managing Director

UK parliament steps up plans for medicines access post Brexit

The UK parliament has published contingency legislation to ensure continuity of medicines access and clinical trials in the event of a no deal Brexit.

Dr Frances Macdonald joins the Lightning Health network

The Lightning Health team is delighted to announce Dr Frances Macdonald is joining the network as an executive advisor for European HTA.

The NHS England long term plan

NHS England has published its long-awaited long-term NHS plan, setting out the strategic objectives for the NHS over the next 10 years.